What Lomond Therapeutics does

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies. The company's pipeline is anchored by three differentiated programs: Lomonitinib, a pan-FLT3/IRAK4 inhibitor in Phase 1b trials in Australia and the United States for relapsed/refractory AML driven by FLT3 mutations; Lonitoclax, a next-generation BCL-2 inhibitor with best-in-class selectivity for BCL-2 over BCL-XL and no CYP3A4 liability, in Phase 1 trials for CLL, SLL, low-grade lymphomas, and now AML; and a menin inhibitor program licensed from Bala Therapeutics in pre-clinical/IND-enabling work for NPM-1 and MLL-rearranged AML. Lomond is a development-stage spin-out of Eilean Therapeutics LLC and leverages Eilean's proprietary hybrid AI platform, Expert Systems Inc., which combines proprietary chem-bio data, knowledge, and tools for multi-target, multi-property optimization and rational compound design.

The company employs 11–50 people and is incorporated in Delaware (Lomond Therapeutics Holdings, Inc.) following its November 2024 reverse merger with Venetian-1 Acquisition Corp, a Montrose Capital SPAC. Lomond is pre-revenue; commercialization upon regulatory approval will rely on traditional pharmaceutical distribution channels including specialty pharmacies, hospital buying groups, and oncology specialty distributors. Capital structure is anchored by co-founders and lead investors OrbiMed and Torrey Pines Investment, with Deerfield Management leading the $44 million private placement closed alongside the reverse merger, and Yosemite Management and Qatar Investment Authority joining in a $20 million follow-on in March 2025, bringing cumulative funding to approximately $64 million. Scientific leadership is anchored by co-founder Dr. John C. Byrd (Chairman of the Scientific Advisory Board and Interim CMO) and the University of Cincinnati Leukemia Drug Development Laboratory, with CEO Iain Dukes (also an OrbiMed Venture Partner) leading the management team alongside CSO Amy Burd and CDO Brian Ledwith.

Name

Lomond Therapeutics

Legal name

Lomond Therapeutics Holdings, Inc.

Website

https://www.lomondther.com/

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies, with three programs (lomonitinib, lonitoclax, menin inhibitors) addressing FLT3-mutated AML, BCL-2-driven CLL/AML, and NPM-1/MLL-rearranged AML.

Ownership category

akta.pro rank

Product category

Hematologic Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Small molecule oncology
• Hematologic cancer therapeutics
• Clinical-stage biotechnology
• Targeted cancer therapy
• Drug discovery platform

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage company. Expected to generate revenue through commercialization of novel small molecule therapeutics for hematologic malignancies upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies. Its pipeline comprises three differentiated programs: Lomonitinib (a pan-FLT3/IRAK4 inhibitor in Phase 1b for AML), Lonitoclax (a next-generation BCL-2 inhibitor in Phase 1 for CLL and AML), and a Menin inhibitor program (preclinical) for NPM-1 and MLL-rearranged AML. The company leverages a proprietary hybrid AI drug discovery platform to accelerate rational small molecule design.

Product overview

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of small molecule oncology drug candidates targeting escape mutations in hematologic malignancies. The company's portfolio consists of three differentiated programs: Lomonitinib (pan-FLT3/IRAK4 inhibitor for AML in Phase 1b), Lonitoclax (BCL-2 inhibitor for CLL and AML in Phase 1), and Menin Inhibitors (for NPM-1 and MLL-rearranged AML in discovery). The company leverages a proprietary hybrid AI platform to accelerate rational drug design and development of best-in-class and first-in-class therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Lomonitinib A novel, highly potent and selective pan-FLT3/IRAK4 inhibitor designed to block activity of all major known FLT3 resistance mutations (ITD, TKD, and other clinically relevant mutations) and IRAK4 simultaneously in acute myeloid leukemia. In Phase 1b clinical development in Australia and the United States for relapsed/refractory AML patients with FLT3 mutations.
• Lonitoclax A next-generation, oral once-daily BCL-2 inhibitor designed with a unique binding mode to improve selectivity for BCL-2 over BCL-XL, mitigate hematologic and immune toxicities seen with venetoclax, and avoid CYP3A4 drug-drug interactions. In Phase 1 clinical development for relapsed/refractory CLL, small lymphocytic lymphoma, select low-grade lymphomas, and AML.
• Menin Inhibitor Program A class of menin inhibitors licensed exclusively from Bala Therapeutics for the treatment of NPM-1 and MLL-rearranged acute myeloid leukemia. In discovery/IND-enabling stage with candidate selection expected in second half of 2025.

Quantifiable outcome

• Lonitoclax demonstrated no significant safety signals at exposures where robust BCL-2 inhibition was achieved in Phase 1 healthy volunteer studies
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Venetian-1 Acquisition CorpcoreStrategic or Co-development Partner · 4 November 2024Lomond Therapeutics completed a reverse merger transaction with Venetian-1 Acquisition Corp (sponsored by Montrose Capital). Following the merger, Venetian-1 was renamed Lomond Therapeutics Holdings, Inc.
• Eilean Therapeutics LLCcoreStrategic or Co-development PartnerLomond Therapeutics is a spin-out/clinical-stage subsidiary of Eilean Therapeutics LLC, a precision oncology-focused discovery and development platform. The company leverages Eilean's proprietary hybrid AI platform, Expert Systems Inc., for drug discovery and development. Pre-clinical work was conducted by Eilean in collaboration with the Leukemia Drug Development Laboratory at the University of Cincinnati.
• University of Cincinnati (Leukemia Drug Development Laboratory)coreStrategic or Co-development PartnerPre-clinical work for lonitoclax and lomonitinib was conducted in collaboration with the Leukemia Drug Development Laboratory at the University of Cincinnati, led by Dr. John C. Byrd and Dr. Erin Hertlein.

Scale indicators3 records

Recent moves10 records

Expansion highlights5 records

Emerging players

• Schrödinger, Inc. AI-driven computational drug discovery platform with oncology pipeline programs — comparable to Lomond's hybrid AI/Expert Systems discovery engine and emerging clinical-stage pipeline.
• Kymera Therapeutics: Clinical-stage developer of targeted protein degraders using a computationally-enabled discovery platform — comparable to Lomond's stated protein degrader/molecular glue modality capabilities.
• Recursion Pharmaceuticals: AI/ML-driven drug discovery company with pipeline across oncology and rare diseases — overlaps Lomond's hybrid AI platform approach to small molecule design.

Direct peers

• Foghorn Therapeutics: Clinical-stage biotech developing chromatin-based small molecule therapies for hematologic cancers including AML — directly comparable in target class, indication focus, and clinical maturity.
• Kura Oncology: Clinical-stage oncology company developing menin inhibitors (ziftomenib) and a tipifarnib-based program for hematologic malignancies — directly comparable to Lomond's menin and FLT3 programs targeting similar genetically-defined AML populations.
• Aptose Biosciences: Clinical-stage developer of small molecule kinase inhibitors for hematologic cancers (luxeptinib, tuspetinib) — comparable pipeline scope, indication focus, and clinical-stage risk profile to Lomond.
• Syndax Pharmaceuticals: Commercial-stage developer of revumenib (menin inhibitor, approved for KMT2A-rearranged AML) — directly competing in Lomond's menin inhibitor indication and representing the bar Lomond must beat.

Broad incumbents

• AbbVie: Developer of venetoclax (Venclexta), the entrenched BCL-2 inhibitor Lomond's lonitoclax must differentiate against — also a likely strategic acquirer given portfolio fit.
• Astellas Pharma: Developer of gilteritinib (Xospata), the established FLT3 inhibitor for relapsed/refractory AML that Lomond's lomonitinib is designed to improve upon.
• Daiichi Sankyo: Developer of quizartinib (Vanflyta), approved FLT3 inhibitor for newly diagnosed FLT3-ITD AML — incumbent Lomond must clinically differentiate against in pan-FLT3 AML.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/LomondTher

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lomond Therapeutics